Title: Diagnostic Efficacy of ERG and CK5 Coexpression in Prostatic Intraepithelial Neoplasia and Carcinoma
Authors: Dr Madhu Kumar, Dr Piyush Sagar, Prof Suresh Babu, Prof S N Shankwar, Prof Nushat Hussain
DOI: https://dx.doi.org/10.18535/jmscr/v4i12.29
Abstract
Background: Prostate lesions either benign, Premalignant or malignant, continues to be distressing and annoying problem for old people from centuries. Carcinoma of prostate is most common internal malignancy among men & is responsible for 10% of cancer death in the population. The combination of ERG and CK5 provides a unique stain that identifies the TMPRSS2-ERG chromosomal translocation in prostate cancer. The current study aims to detect the diagnostic efficacy of ERG & CK5 co-expression in BPH, PIN & Prostatic carcinoma.
Aims & Objectives: Study of coexpression of ERG & CK5 immunohistochemical stain in BPH, PIN and Prostatic carcinoma and to correlate with serum PSA level, tumor stage and grade.
Materials & Methods: We received TURP and Tru-cut biopsy specimen for histopathological examination. Specimens were processed, sections cut, stained with Hematoxylin & Eosin as well as apply cocktail of ERG & CK5 immunohistochemical stain as per standard protocol.
Results & Discussion: On the basis of histology, 11 cases were Benign Prostatic Hyperplasia (37%), 9 cases were Benign Prostatic Hyperplasia with Prostatic Intraepithelial Neoplasia (30%) and 10 cases (33%) were prostatic carcinoma.
Sensitivity and specificity of ERG&CK5 immunostain in detecting ERG positive prostatic adenocarcinoma being 70% and 100% respectively in our study. Thus staining for ERG&CK5 has great utility in resolving diagnostic problems of PIN and adenocarcinoma prostate cases that arises in prostatic needle biopsies containing small foci of suspicious cells.
Conclusion: However immunohistochemical stain is an important adjunct to the diagnosis and predictive analysis of prostate biopsy specimens.
Keywords: Immunohistochemical stain, ERG, CK5, TURP & Tru-cut biopsy of Prostate.
References
1. Kearse WS Jr, Seay TM , Thompson IM. Long term risk of development of prostate cancer in patients with BHP. Correlation with stage A1 disease. J Uro 1993; 150: 1746-1748.
2. Brawer MK. Prostatic intraepithelial neoplasia. A premalignant lesion. Hum Pathol 1992;23: 242-248.
3. Furusato B, Tan SH, Young D, et al. ERG oncoprotein expression in prostate cancer, clonal progression of ERG- positive tumor cells and potential for ERG-based stratification. Prostate cancer Prostatic Dis 2010;13: 228-237.
4. Transurethral incision of the prostate and bladder neck. Journal of Andrology 1991; 12:415- 422.
5. Walsh PC,Jewett HJ: Radical surgery for prostate cancer. Cancer 1980; 45:1906-1911.
6. Keetch DW,Humpherey P.Stahl D,Smith DS,Catalona WJ.Morphometric analysis and clinical follow-up of isolated prostatic intraepithelial neoplasia in needle biopsy of the prostate. J Urol 1995;154:347-51.
7. Davidson D, Bostwick DG, Qian et al,Prostatic Intraepithelial neoplasia is a risk factor for adenocarcinoma. J Urol 1995;154:1295-9.
8. Kovi J, Mostofi FK, Heshmat MY et al.: Large acinar-atypical hyperplasia and carcinoma of prostate. Cancer 1988; 61: 555-61.
9. Transco P, Babain R, Grignon DJ et al.: Prostatic intraepithelial neoplasia and invasive adenocarcinoma in cytoprostect-omy specimen. Urology 1989;34: 52-56.
10. Aboseif S, Shinohara H et al: Significance of prostatic intraepithelial Neoplasia. Br J Urol 1995;76: 355-359.
11. Weinstein MH & Epstein Jl: Significance of High grade Prostatic Intraepithelial Neoplasia on needle biopsy. Hum Path 1993; 24: 624.
12. Gaudin PB, Sestelenn IA, Mostofi FK et al: Incidence and clinical significance of High Grade Prastatic Intaepithelial Neoplasiain TURP specimen. Urology 1997; 49: 558-63.
13. Bonkhoff H, Remberger K: Diagnostic criteria and differential diagnosis of prostatic intra-epithelial Neoplasia. Patholge. 1998; 19: 33-41.
14. Porter AT, Pontes JE, Grgnon DJ: Diagnostic and prognostic marker for human prostate cancer. Prostate 1997; 31:264-81.
15. Shah et al. Comparison of basal cell specific marker, 34 pE12 and p63 in the diagnosis of prostate cancer. Am J of Surg Path 2002; 26:1161-1168.